Before UW
Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, Kim SY, Klaeger S, Knudsen NH, Miller BC, Nguyen TH, Olander KE, Papanastasiou M, Rachimi S, Robitschek EJ, Schneider EM, Yeary MD, Zimmer MD, Jaffe JD, Carr SA, Doench JG, Haining WN, Yates KB, Manguso RT, Bernstein BE. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021 Jul;595(7866):309-314. doi: 10.1038/s41586-021-03520-4. Epub 2021 May 5. PMID: 33953401.

Dubrot J, Lane-Reticker SK, Kessler EA, Ayer A, Mishra G, Wolfe CH, Zimmer MD, Du PP, Mahapatra A, Ockerman KM, Davis TGR, Kohnle IC, Pope HW, Allen PM, Olander KE, Iracheta-Vellve A, Doench JG, Haining WN, Yates KB, Manguso RT. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity. 2021 Mar 9;54(3):571-585.e6. doi: 10.1016/j.immuni.2021.01.001. Epub 2021 Jan 25. PMID: 33497609.

Wu MJ, Shi L, Dubrot J, Merritt J, Vijay V, Wei TY, Kessler E, Olander KE, Adil R, Pankaj A, Tummala KS, Weeresekara V, Zhen Y, Wu Q, Luo M, Shen W, García-Beccaria M, Fernández-Vaquero M, Hudson C, Ronseaux S, Sun Y, Saad-Berreta R, Jenkins RW, Wang T, Heikenwälder M, Ferrone CR, Goyal L, Nicolay B, Deshpande V, Kohli RM, Zheng H, Manguso RT, Bardeesy N. Mutant IDH Inhibits IFNγ-TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma. Cancer Discov. 2022 Mar 1;12(3):812-835. doi: 10.1158/2159-8290.CD-21-1077. PMID: 34848557; PMCID: PMC8904298.

Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM, Wolfe CH, Wiesmann F, Knudsen NH, Tsao HW, Iracheta-Vellve A, Schneider EM, Rivera-Rosario AN, Kohnle IC, Pope HW, Ayer A, Mishra G, Zimmer MD, Kim SY, Mahapatra A, Ebrahimi-Nik H, Frederick DT, Boland GM, Haining WN, Root DE, Doench JG, Hacohen N, Yates KB, Manguso RT. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022 Oct;23(10):1495-1506. doi: 10.1038/s41590-022-01315-x. Epub 2022 Sep 23. PMID: 36151395.

Christina K. Baumgartner1, Hakimeh Ebrahimi-Nik, Arvin Iracheta-Vellve, Keith M. Hamel, Kira Olander, Thomas G.R Davis, Kathleen A. McGuire, Geoff T. Halvorsen, Omar I. Avila, Chirag Patel, Sarah Kim, Ashwin V. Kammula, Audrey J. Muscato, Kyle Halliwill, Prasanthi Geda, Kelly L. Klinge, Zhaoming Xiong, Ryan Duggan, Liang Mu, Mitchell D. Yeary, James C. Patti, Tyler M. Balon, Rebecca Mathew, Carey Backus, Domenick Kennedy, Angeline Chen, Kenton Longenecker, Joseph T. Klahn, Cara Hrusch, Navasona Krishnan, Charles W. Hutchins, Jacqueline D. Aguado, Marinka Bulic, Payal Tiwari, Kayla J. Colvin, Cun Lan Chuong, Ian C. Kohnle, Matthew G. Rees, Andrew Boghossian, Melissa Ronan, Jennifer A. Roth, Meng-Ju Wu, Debattama R. Sen, Gabriel K. Griffin, Nabeel El-Bardeesy4 Patricia Trusk, Meng Sun, Yue Liu, Joshua H Decker,Yi Yang, Stacey Fossey, Wei Qiu, Qi Sun, Marcia N. Paddock, Elliot P. Farney, Clay Beauregard, Jennifer M. Frost, Kathleen B. Yates, Philip R. Kym,  and Robert T. Manguso. PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity. Manuscript in preparation